Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic
- PMID: 33705648
- PMCID: PMC10734871
- DOI: 10.3906/sag-2101-276
Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic
Abstract
Background/aim: The COVID-19 pandemic is a unique challenge to the care of patients with hematological malignancies. We aim to provide supportive guidance to clinicians making individual patients decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited.
Conclusion: This review also provides recommendations, which are convenient in evaluating indications for therapy, reducing therapy-associated immunosuppression, and reducing healthcare utilization in patients with specific hematological malignancies in the COVID-19 era. Specific decisions regarding treatment of hematological malignancies will need to be individualized, based on disease risk, risk of immunosuppression, rates of community transmission of SARS-CoV-2, and available local healthcare resources.
Keywords: COVID-19; SARS-CoV-2; hematological malignancies.
Conflict of interest statement
All authors disclose no conflict of interest.
References
-
- Ljungman P, Mikulska M, De la Camara R, Basak GW, Chabannon C, et al. European Society for Blood and Marrow Transplantation: the challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation. 2020;55(11):2071–2076. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
